Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Jan, 2015 | Pages:
250 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Glaucoma - Pipeline Review, H1 2015 Summary Global Markets Direct's, 'Glaucoma - Pipeline Review, H1 2015', provides an overview of the Glaucoma's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Glaucoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Glaucoma and special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Glaucoma - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Glaucoma and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Glaucoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Glaucoma pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Glaucoma - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Glaucoma pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents Table of Contents 2 List of Tables 7 List of Figures 9 Introduction 10 Global Markets Direct Report Coverage 10 Glaucoma Overview 11 Therapeutics Development 12 Pipeline Products for Glaucoma - Overview 12 Pipeline Products for Glaucoma - Comparative Analysis 13 Glaucoma - Therapeutics under Development by Companies 14 Glaucoma - Therapeutics under Investigation by Universities/Institutes 18 Glaucoma - Pipeline Products Glance 19 Late Stage Products 19 Clinical Stage Products 20 Early Stage Products 21 Unknown Stage Products 22 Glaucoma - Products under Development by Companies 23 Glaucoma - Products under Investigation by Universities/Institutes 29 Glaucoma - Companies Involved in Therapeutics Development 30 AC Immune SA 30 Acadia Pharmaceuticals Inc. 31 Aerie Pharmaceuticals, Inc. 32 Alcon, Inc. 33 Allergan, Inc. 34 Altacor Ltd. 35 Amakem NV 36 Asahi Kasei Pharma Corp. 37 AUS Bio Limited 38 Bausch & Lomb Incorporated 39 Bionure Farma, S.L. 40 Can-Fite BioPharma Ltd. 41 Cellular Biomedicine Group, Inc. 42 China Grand Wuhan General Pharmaceutical Research Institute 43 D. Western Therapeutics Institute, Inc. 44 DNAVEC Corporation 45 Dompe Farmaceutici S.p.A. 46 F. Hoffmann-La Roche Ltd. 47 Foamix Pharmaceuticals Ltd. 48 Gene Signal International SA 49 Gilead Sciences, Inc. 50 Handok Inc. 51 High Point Pharmaceuticals, LLC 52 Icon Bioscience, Inc. 53 IMMD Inc. 54 Inotek Pharmaceuticals Corporation 55 InSite Vision Incorporated 56 Lacer, S.A. 57 Merck & Co., Inc. 58 Merz Pharma GmbH & Co. KgaA 59 Mimetogen Pharmaceuticals Inc. 60 NeoStem, Inc. 61 Neurotech Pharmaceuticals, Inc. 62 NicOx S.A. 63 Ocata Therapeutics, Inc. 64 Ocular Therapeutix, Inc. 65 Ohr Pharmaceutical Inc. 66 Ono Pharmaceutical Co., Ltd. 67 Otsuka Holdings Co., Ltd. 68 Oxford BioMedica plc 69 PharmaNova Inc. 70 Quark Pharmaceuticals, Inc. 71 Santen Pharmaceutical Co., Ltd. 72 Senju Pharmaceutical Co., Ltd. 73 SIFI S.p.A 74 SK Biopharmaceuticals Co., Ltd. 75 Sun Pharma Advanced Research Company Ltd. 76 Sylentis S.A. 77 Teva Pharmaceutical Industries Limited 78 Upsher-Smith Laboratories, Inc. 79 Glaucoma - Therapeutics Assessment 80 Assessment by Monotherapy Products 80 Assessment by Combination Products 81 Assessment by Target 82 Assessment by Mechanism of Action 86 Assessment by Route of Administration 90 Assessment by Molecule Type 92 Drug Profiles 94 (AR-13324 + latanoprost) - Drug Profile 94 (bimatoprost + brimonidine tartrate) - Drug Profile 95 (carteolol hydrochloride + latanoprost) - Drug Profile 96 (dorzolamide hydrochloride + latanoprost) - Drug Profile 97 (latanoprost + trabodenoson) - Drug Profile 98 (Prostaglandin Agonist + Beta-Blocker) - Drug Profile 99 (tafluprost + timolol maleate) - Drug Profile 100 AC-262271 - Drug Profile 101 ACI-260 - Drug Profile 102 ACN-1052 - Drug Profile 103 aganirsen - Drug Profile 104 ALT-022 - Drug Profile 106 AMA-0076 - Drug Profile 107 Antibody to Inhibit Sema3A for Glaucoma and Optic Neuropathy - Drug Profile 108 AP-022 - Drug Profile 109 APH-1104 - Drug Profile 110 AR-13324 - Drug Profile 111 AR-13533 - Drug Profile 112 ATS-8535 - Drug Profile 113 BA-1049 - Drug Profile 114 BA-240 - Drug Profile 115 bimatoprost - Drug Profile 116 bimatoprost SR - Drug Profile 117 BN-201 - Drug Profile 118 CF-101 - Drug Profile 119 CNS-102 - Drug Profile 122 DE-117 - Drug Profile 123 dorzolamide hydrochloride nanoparticle - Drug Profile 124 Drugs for Steroid Induced Glaucoma - Drug Profile 125 Drugs to Inhibit Cadherin-5 for Glaucoma - Drug Profile 126 Drugs to Target Bestrophin-2 for Glaucoma - Drug Profile 127 ENV-515 - Drug Profile 128 GB-201 - Drug Profile 129 GB-202 - Drug Profile 130 GB-203 - Drug Profile 131 GB-204 - Drug Profile 132 Gene Therapy for Glaucoma and Retinitis Pigmentosa - Drug Profile 133 Gene Therapy for Ocular Diseases - Drug Profile 134 Gene Therapy for Steroid Induced Glaucoma and Ocular Hypertension - Drug Profile 135 Glaucoma-GT - Drug Profile 136 GS-607601 - Drug Profile 137 H-1129 - Drug Profile 138 H-1129 Backup - Drug Profile 139 HL-5521 - Drug Profile 140 HPP-851 - Drug Profile 141 IMD-1041 - Drug Profile 142 KR-12 - Drug Profile 143 LA-8045 - Drug Profile 144 latanoprost - Drug Profile 145 latanoprost - Drug Profile 146 latanoprost - Drug Profile 148 latanoprost - Drug Profile 149 latanoprost SR - Drug Profile 150 latanoprostene bunod - Drug Profile 152 lomerizine - Drug Profile 154 Lycium Anti-Angiogenic Proteoglycan - Drug Profile 155 MD-920G - Drug Profile 156 MIMD-3 - Drug Profile 157 minocycline Gel - Drug Profile 158 Monoclonal Antibody to Activate Bves for Glaucoma - Drug Profile 159 MRZ-99030 - Drug Profile 160 NB-1111 - Drug Profile 161 NCX-1021 - Drug Profile 162 NCX-250 - Drug Profile 163 Neurovitas - Drug Profile 164 NT-501 - Drug Profile 165 NT-509 - Drug Profile 167 ONO-9054 - Drug Profile 168 OPA-6566 - Drug Profile 169 PBF-695 - Drug Profile 170 PRX-00933 - Drug Profile 171 QPI-1007 - Drug Profile 172 R-807 - Drug Profile 173 Recombinant Human Nerve Growth Factor - Drug Profile 174 RO-5093151 - Drug Profile 175 SF-103 - Drug Profile 177 SF-108 - Drug Profile 178 SF-109 - Drug Profile 179 SF-116 - Drug Profile 180 SKL-G - Drug Profile 181 SKS-1002 - Drug Profile 182 Small Molecule for Glaucoma - Drug Profile 183 Small Molecule for Glaucoma - Drug Profile 184 Small Molecule to Inhibit Rho Kinase for Glaucoma - Drug Profile 185 Small Molecule to Inhibit Sema3A for Glaucoma and Optic Neuropathy - Drug Profile 186 Small Molecules for CNS Disorders and Ophthalmology - Drug Profile 187 Small Molecules to Activate sGC for Ophthalmology - Drug Profile 188 Small Molecules to Antagonize TRPM7 for Myocardial Ischemia and Glaucoma - Drug Profile 189 Small Molecules to Antagonize TRPV4 for Glaucoma - Drug Profile 190 Small Molecules to Inhibit LIMK1 AND LIMK2 for Cancer and Ophthalmology - Drug Profile 191 SNJ-1656 - Drug Profile 192 SNJ-1945 - Drug Profile 194 Stem Cell Therapy for Glaucoma - Drug Profile 195 Stem Cell Therapy for Glaucoma, Cerebral Palsy and Lupus - Drug Profile 196 Stem Cell Therapy for Macular Degeneration and Glaucoma - Drug Profile 197 Stem Cell Therapy for Ophthalmic Disorders - Drug Profile 198 SYL-040012 - Drug Profile 199 Synthetic Peptide for Glaucoma - Drug Profile 201 tafluprost - Drug Profile 202 trabodenoson - Drug Profile 204 travoprost SR - Drug Profile 205 TRV-32R - Drug Profile 206 XY-0811QF2 - Drug Profile 207 XY-1303LT2 - Drug Profile 208 Glaucoma - Recent Pipeline Updates 209 Glaucoma - Dormant Projects 230 Glaucoma - Discontinued Products 232 Glaucoma - Product Development Milestones 233 Featured News & Press Releases 233 Appendix 242 Methodology 242 Coverage 242 Secondary Research 242 Primary Research 242 Expert Panel Validation 242 Contact Us 243 Disclaimer 243
List of Tables Number of Products under Development for Glaucoma, H1 2015 19 Number of Products under Development for Glaucoma - Comparative Analysis, H1 2015 20 Number of Products under Development by Companies, H1 2015 21 Number of Products under Investigation by Universities/Institutes, H1 2015 25 Comparative Analysis by Late Stage Development, H1 2015 26 Comparative Analysis by Clinical Stage Development, H1 2015 27 Comparative Analysis by Early Stage Development, H1 2015 28 Comparative Analysis by Unknown Stage Development, H1 2015 29 Products under Development by Companies, H1 2015 30 Products under Development by Companies, H1 2015 (Contd..1) 31 Products under Development by Companies, H1 2015 (Contd..2) 32 Products under Development by Companies, H1 2015 (Contd..3) 33 Products under Development by Companies, H1 2015 (Contd..4) 34 Products under Development by Companies, H1 2015 (Contd..5) 35 Products under Investigation by Universities/Institutes, H1 2015 36 Glaucoma - Pipeline by AC Immune SA, H1 2015 37 Glaucoma - Pipeline by Acadia Pharmaceuticals Inc., H1 2015 38 Glaucoma - Pipeline by Aerie Pharmaceuticals, Inc., H1 2015 39 Glaucoma - Pipeline by Alcon, Inc., H1 2015 40 Glaucoma - Pipeline by Allergan, Inc., H1 2015 41 Glaucoma - Pipeline by Altacor Ltd., H1 2015 42 Glaucoma - Pipeline by Amakem NV, H1 2015 43 Glaucoma - Pipeline by Asahi Kasei Pharma Corp., H1 2015 44 Glaucoma - Pipeline by AUS Bio Limited, H1 2015 45 Glaucoma - Pipeline by Bausch & Lomb Incorporated, H1 2015 46 Glaucoma - Pipeline by Bionure Farma, S.L., H1 2015 47 Glaucoma - Pipeline by Can-Fite BioPharma Ltd., H1 2015 48 Glaucoma - Pipeline by Cellular Biomedicine Group, Inc., H1 2015 49 Glaucoma - Pipeline by China Grand Wuhan General Pharmaceutical Research Institute, H1 2015 50 Glaucoma - Pipeline by D. Western Therapeutics Institute, Inc., H1 2015 51 Glaucoma - Pipeline by DNAVEC Corporation, H1 2015 52 Glaucoma - Pipeline by Dompe Farmaceutici S.p.A., H1 2015 53 Glaucoma - Pipeline by F. Hoffmann-La Roche Ltd., H1 2015 54 Glaucoma - Pipeline by Foamix Pharmaceuticals Ltd., H1 2015 55 Glaucoma - Pipeline by Gene Signal International SA, H1 2015 56 Glaucoma - Pipeline by Gilead Sciences, Inc., H1 2015 57 Glaucoma - Pipeline by Handok Inc., H1 2015 58 Glaucoma - Pipeline by High Point Pharmaceuticals, LLC, H1 2015 59 Glaucoma - Pipeline by Icon Bioscience, Inc., H1 2015 60 Glaucoma - Pipeline by IMMD Inc., H1 2015 61 Glaucoma - Pipeline by Inotek Pharmaceuticals Corporation, H1 2015 62 Glaucoma - Pipeline by InSite Vision Incorporated, H1 2015 63 Glaucoma - Pipeline by Lacer, S.A., H1 2015 64 Glaucoma - Pipeline by Merck & Co., Inc., H1 2015 65 Glaucoma - Pipeline by Merz Pharma GmbH & Co. KgaA, H1 2015 66 Glaucoma - Pipeline by Mimetogen Pharmaceuticals Inc., H1 2015 67 Glaucoma - Pipeline by NeoStem, Inc., H1 2015 68 Glaucoma - Pipeline by Neurotech Pharmaceuticals, Inc., H1 2015 69 Glaucoma - Pipeline by NicOx S.A., H1 2015 70 Glaucoma - Pipeline by Ocata Therapeutics, Inc., H1 2015 71 Glaucoma - Pipeline by Ocular Therapeutix, Inc., H1 2015 72 Glaucoma - Pipeline by Ohr Pharmaceutical Inc., H1 2015 73 Glaucoma - Pipeline by Ono Pharmaceutical Co., Ltd., H1 2015 74 Glaucoma - Pipeline by Otsuka Holdings Co., Ltd., H1 2015 75 Glaucoma - Pipeline by Oxford BioMedica plc, H1 2015 76 Glaucoma - Pipeline by PharmaNova Inc., H1 2015 77 Glaucoma - Pipeline by Quark Pharmaceuticals, Inc., H1 2015 78 Glaucoma - Pipeline by Santen Pharmaceutical Co., Ltd., H1 2015 79 Glaucoma - Pipeline by Senju Pharmaceutical Co., Ltd., H1 2015 80 Glaucoma - Pipeline by SIFI S.p.A, H1 2015 81 Glaucoma - Pipeline by SK Biopharmaceuticals Co., Ltd., H1 2015 82 Glaucoma - Pipeline by Sun Pharma Advanced Research Company Ltd., H1 2015 83 Glaucoma - Pipeline by Sylentis S.A., H1 2015 84 Glaucoma - Pipeline by Teva Pharmaceutical Industries Limited, H1 2015 85 Glaucoma - Pipeline by Upsher-Smith Laboratories, Inc., H1 2015 86 Assessment by Monotherapy Products, H1 2015 87 Assessment by Combination Products, H1 2015 88 Number of Products by Stage and Target, H1 2015 90 Number of Products by Stage and Mechanism of Action, H1 2015 94 Number of Products by Stage and Route of Administration, H1 2015 98 Number of Products by Stage and Molecule Type, H1 2015 100 Glaucoma Therapeutics - Recent Pipeline Updates, H1 2015 216 Glaucoma - Dormant Projects, H1 2015 237 Glaucoma - Discontinued Products, H1 2015 239
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
